

**Kathleen Carroll, Ph.D.**

Associate Professor of Psychiatry  
Division of Substance Abuse  
Yale University School of Medicine  
Veterans Affairs Connecticut Healthcare Center  
West Haven, Connecticut

**R. Lorraine Collins, Ph.D.**

Senior Research Scientist  
Research Institute on Addictions  
State University of New York, University at Buffalo  
Buffalo, New York

**T. Ron Jackson, M.S.W.**

Executive Director  
Evergreen Treatment Services  
University of Washington School of Social Work  
Seattle, Washington

**Herbert D. Kleber, M.D.**

Director, Division on Substance Abuse  
New York State Psychiatric Institute  
Professor, Department of Psychiatry  
College of Physicians and Surgeons of Columbia University  
New York, New York

**Marsha M. Linehan, Ph.D.**

Professor, Department of Psychology  
University of Washington  
Seattle, Washington

**Charles P. O'Brien, M.D., Ph.D.**

Chief of Psychiatry  
Department of Psychiatry  
Philadelphia Veterans Affairs Medical Center  
Treatment Research Center  
University of Pennsylvania  
Philadelphia, Pennsylvania

**Lisa Onken, Ph.D.**

Chief, Behavioral Treatment Development Branch  
Division of Treatment Research and Development  
National Institute on Drug Abuse  
Bethesda, Maryland

**John Schwarzlose, Ph.D.**

Executive Director  
Betty Ford Center  
Rancho Mirage, California

**Jack B. Stein, Ph.D.**

Deputy Director, Office of Science Policy and Communications  
National Institute on Drug Abuse  
Bethesda, Maryland

**Constance M. Weisner, Dr.P.H., M.S.W.**


Professor, Department of Psychiatry  
University of California, San Francisco  
Adjunct Investigator  
Division of Research, Kaiser Permanente  
San Francisco, California

## Two Perspectives, One Goal

Drug abuse researchers and service providers have markedly different professional vocabularies and points of view. To cite just a few examples: Researchers focus on *outcomes*, while treatment providers promote *recovery*; clinicians work one-on-one to make a difference for individual patients, while researchers tend to compare the experiences of groups, looking for widely applicable insights into drug abuse and its treatment; the time frame in the clinic is as immediate as human emotion or personal emergency, while research—of necessity—moves painstakingly toward the goal of advancing human understanding to realize future improvements.

Despite their different perspectives, what unites drug abuse researchers and practitioners is much stronger than what separates them. In NIDA's National Drug Abuse Treatment Clinical Trials Network (CTN), we have clearly seen that scientists and practitioners are eager and able to combine their efforts to achieve the common goal of reducing drug abuse and the damage it wreaks. Although CTN is only 2 years old, its membership already includes 14 regional research centers and 93 community treatment programs. Scientists and treatment providers have agreed upon 12 specific research concepts and worked together to design 7 trial protocols that meet clinics' need for economical operations and researchers' needs for rigorous data.

Rich interprofessional exchanges and collaborations, such as those taking place in CTN and elsewhere, are essential to improving the effectiveness of drug abuse treatment and prevention to the greatest degree and at the most rapid pace. Toward that end, *Science & Practice Perspectives* will play an important role by helping scientists and service providers share information and provide mutual inspiration.



Glen R. Hanson, Ph.D., D.D.S.

Acting Director

National Institute on Drug Abuse